JFL Life Sciences Limited IPO Allotment, Refund and Listing Date
| JFL Life Sciences Limited IPO Opening Date | August 25, 2022 |
| JFL Life Sciences Limited IPO Closing Date | August 30, 2022 |
| Basis of Allotment | September 5, 2022 |
| Initiation of Refunds | September 6, 2022 |
| Credit of Shares to Demat | September 7, 2022 |
| JFL Life Sciences Limited IPO Listing Date | September 8, 2022 |
JFL Life Sciences Limited IPO Details
| JFL Life Sciences Limited IPO Price Band | Rs.61 Per Equity Share |
| IPO Lot Size | Minimum 2000 shares for 1 lot |
| Minimum Amount | Rs.114,000 for 1 lot |
| IPO Size | Approx Rs.18.17 Crores |
| Listing At | BSE, NSE |
| Offer for Sale | 2,978,000 Equity Shares |
| Retail Quota: | 50% |
| QIB Quota: | – |
| NII Quota: | 50% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
JFL Life Sciences Limited IPO GMP (Grey Market Premium)
| Date | GMP | Kostak | Subject to |
| 31 August | RS.5 | – | Rs.20000 |
JFL Life Sciences Limited IPO Subscription Status Live
| Investor Category | Subscription (times) |
|---|---|
| Qualified Institutions | – |
| Non-Institutional Buyers | 6.19 |
| Retail Investors | 11.60 |
| Employees | – |
| Others | – |
| Total | 8.93 |
JFL Life Sciences Limited IPO Subscription Details (times)
| Date | NII | Retail | Total |
|---|---|---|---|
| Day 1 Aug 25, 2022 | 0.24 | 0.75 | 0.49 |
| Day 2 Aug 26, 2022 | 0.51 | 1.65 | 1.08 |
| Day 3 Aug 29, 2022 | 0.66 | 3.71 | 2.19 |
| Day 4 Aug 30, 2022 | 6.19 | 11.66 | 8.93 |
JFL Life Sciences Limited Financial Report
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus |
|---|---|---|---|---|---|
| 31-Aug-19 | 1614.96 | 3177.96 | 30.25 | 501.49 | 459.2 |
| 31-Mar-20 | 2432.59 | 3020.41 | 36.04 | 537.53 | 495.24 |
| 31-Mar-21 | 2900.69 | 3286.89 | 54.21 | 687.25 | 637.55 |
| 28-Feb-22 | 3662.86 | 2563.06 | 253.28 | 1096.52 | 294.48 |
JFL Life Sciences Limited IPO Valuation – FY-2022
| Earning Per Share (EPS): | Rs.0.76 per Equity Share |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 7.18% |
JFL Life Sciences Limited IPO Review
| What our Expert say about JFL Life Sciences Limited IPO Review | Avoid |
Peer Group
- Zenith Health Care Limited
- Vaishali Pharma Limited
Objects of the Issue
- Repayment of secured and unsecured loans.
- Funding the working capital requirements of the company.
- General Corporate Purposes
JFL Life Sciences Limited IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: jfl.ipo@kfintech.com
Website: https://karisma.kfintech.com/
Company Promoters
- Smiral Ashwinkumar Patel
- Tejal Smiral Patel
About JFL Life Sciences Limited
Let us take a deep look at the company and analysis on the IPO date, offering price, subscription, allocation, price on the JFL Life Sciences Limited IPO, gray market, and other details such as companys background, financials, its promoters, and other relevant stuff. The promoters, Mr. Smiral Ashwinbhai Patel and Tejal Smiralbhai Patel are heavily involved in day-to-day operations of JFL Life Sciences Limited and are guiding forces behind strategic decisions for the company. JFL Life Sciences Pvt. Ltd has been the trailblazer for meeting orders on a timely basis and has developed good links with the corporate giants and who is who of the industry, which itself has been a promising road ahead for the Company towards bright and prosperous future. JFL Life Sciences is exporting its portfolio primarily in African countries, Middle Eastern countries, and CIS countries, mostly through trade exporters.
JFL Life Science Limiteds sales strategy is to sell bulk quantities of the Companys product portfolio to drug marketers and traders, which, in turn, provides a sales channel to customers. Based out Ahmedabad, Gujarat, pharma companies are engaged in manufacturing pharmaceutical products. Established as a Private Limited Company in Bavla, the company is known for being one of the leading manufacturers of quality products/services like injectables, health checkup, stability testing, comprehensive analytical services, pilot-scale, products/services offered are known for features such as high-quality, competitive pricing, required features, and low-maintenance.
The company is one of the largest dry powder injection drug companies with WHO-GMP certification in India. To keep the pharmaceutical companies competitive and to promote healthcare, JFL has laid down a robust R&D base as well as an FDA-approved, modern manufacturing plant just outside of Ahmedabad.
Our Companys Corporate Identification Number is U24230GJ2010PLC060417. The Company was converted from Private limited Company to Public limited Company, Consequently, our Companys name was changed to JFL Life Science Limited, and we were issued with fresh Certificate of Incorporation on 03-03-2022 from the Registrar of Companies, Gujarat, at Ahmedabad.
The issued shares and net worth will form 27.08 % and 25.71 %, respectively, of JFL Life Sciences Limiteds paid-up equity share capital after the issuance. The Total subscription status for the JFL Life Sciences IPO has been subscribed 8.93 times till date, QIB has been subscribed 0.0x times, and NII has been subscribed 6.19x times, and RII has been subscribed 11.66x times, while EMP has been subscribed 0.0x times till day 4.
Tejal Smiral Patel, aged 40 years, is a full-time director and one of the promoters of the Company. I. Smiral Ashwinkumar Patel is the Chairman of the Board of Directors and Non-Executive Director of the Company.
Company Address
JFL Life Sciences Limited
309, Satyam Mall,
Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir
Settelite, Ahmedabad 380015
Phone: 937729 5575
Email: cs@jfllifesciences.com
Website: http://www.jfllifesciences.com/
